Drug products: Ketorolac EG, Ketorolac S.A.L.F., Lixidol, Toradol, Tora-dol, Toradol®
ATC code: M01AB15
Substances: ketorolac, ketorolac trometamol
No difference in effect of ketorolac in men and women could be found in an experimental pain model.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of ketorolac have been found.
The analgesic efficacy of ketorolac (10 mg p.o.) was evaluated in an experimental pain method using cold pressor test (25 men, 25 women). No difference between men and women in ketorolac response was found .
A case-control study (136 men, 130 women) found an association between NSAID exposure and liver injury in women but not in men (6.49 vs. 1.06). This may be due to differences in pharmacokinetics or levels of circulating hormones and/or more poly-pharmacy in women  or to a generally higher risk of drug-induced liver injury in women . If this is an adverse effect for NSAIDs in general or only associated with certain NSAIDs is unclear. If ketorolac was included is not specified.
A meta-analysis evaluated NSAID use and the risk of Parkinson’s disease. Pooled risk ratio of Parkinson’s disease were similar in men and women using NSAID (men 0.79; women 0.72) . If this is an effect for NSAIDs in general or only associated with certain NSAIDs is unclear. If ketorolac was included is not specified.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2015-01-26
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson